Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The negative effects on the eradication success of Helicobacter pylori infection after previous exposure to macrolides, including clarithromycin on clarithromycin-based first-line therapy have been demonstrated. However, whether this is true for metronidazole-based second-line quadruple therapy remains unclear. We investigated the relationship between past administration of metronidazole and the failure of metronidazole-based second-line quadruple therapy in patients with H. pylori infection. Methods: Patients over 20 years of age who were diagnosed with H. pylori infection between January 1998 and March 2016 were enrolled in this study. The relationship between the clinical parameters and the results of a C13-urea breath test after metronidazole-based second-line quadruple therapy was analyzed in patients for whom clarithromycin-based triple therapy failed to eradicate H. pylori. Results: The H. pylori eradication failure rate was significantly higher in patients with a history of metronidazole use than in patients without a history of metronidazole use (p = 0.011). Multivariable analysis showed that the odds ratio of previous metronidazole use for eradication failure was 3.468 (95% confidence interval, 1.391 to 8.649; p = 0.008). In the subgroup analysis of patients with a history of metronidazole use, the duration of metronidazole use and interval between its use and eradication therapy did not significantly affect H. pylori eradication failure. Conclusions: Previous exposure to metronidazole was a significant risk factor for treatment failure of metronidazole-based second-line quadruple therapy; therefore, this should be considered when establishing a treatment strategy for patients with H. pylori infection.
Abstract
Background/Aims: The negative effects on the eradication success of Helicobacter pylori infection after previous exposure to macrolides, including clarithromycin on clarithromycin-based first-line therapy have been demonstrated. However, whether this is true for metronidazole-based second-line quadruple therapy remains unclear. We investigated the relationship between past administration of metronidazole and the failure of metronidazole-based second-line quadruple therapy in patients with H. pylori infection. Methods: Patients over 20 years of age who were diagnosed with H. pylori infection between January 1998 and March 2016 were enrolled in this study. The relationship between the clinical parameters and the results of a C13-urea breath test after metronidazole-based second-line quadruple therapy was analyzed in patients for whom clarithromycin-based triple therapy failed to eradicate H. pylori. Results: The H. pylori eradication failure rate was significantly higher in patients with a history of metronidazole use than in patients without a history of metronidazole use (p = 0.011). Multivariable analysis showed that the odds ratio of previous metronidazole use for eradication failure was 3.468 (95% confidence interval, 1.391 to 8.649; p = 0.008). In the subgroup analysis of patients with a history of metronidazole use, the duration of metronidazole use and interval between its use and eradication therapy did not significantly affect H. pylori eradication failure. Conclusions: Previous exposure to metronidazole was a significant risk factor for treatment failure of metronidazole-based second-line quadruple therapy; therefore, this should be considered when establishing a treatment strategy for patients with H. pylori infection.
참고문헌 (42)
- Wang F, "Helicobacter pylori-induced gastric inflammation and gastric cancer", Cancer Lett, 345, pp.196~202 (2014)
- 배종면, "Helicobacter pylori Infection and Risk of Gastric Cancer in Korea: A Quantitative Systematic Review", 예방의학회지, 49(4), pp.197~204 (2016), 대한예방의학회
- 여세환, "헬리코박터 파일로리 연관 소화성 궤양", 대한소화기학회지, 67(6), pp.289~299 (2016), 대한소화기학회
- Thung I, "Review article : the global emergence of Helicobacter pylori antibiotic resistance", Aliment Pharmacol Ther, 43, pp.514~533 (2016)
- Flores-Trevino S, "Helicobacter pylori drug resistance : therapy changes and challenges", Expert Rev Gastroenterol Hepatol, 12, pp.819~827 (2018)
- 공은정, "Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change?", Journal of Korean Medical Science, 29(5), pp.704~713 (2014), 대한의학회
- 김정목, "2003년 우리나라 환자에서 분리한 Helicobacter pylori 균주의 항생제 내성률", 대한소화기학회지, 44(3), pp.126~135 (2004), 대한소화기학회
- Lee JH, "Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults", Antimicrob Agents Chemother, 49, pp.1600~1603 (2005)
- 김성은, "Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy", The Korean Journal of Internal Medicine, 30(6), pp.801~807 (2015), 대한내과학회[DOI]
- Shin WG, "Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use : nationwide survey", Helicobacter, 21, pp.266~278 (2016)
- Woo HY, "Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens", Helicobacter, 14, pp.22~28 (2009)
- Lehours P, "DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin", BMC Gastroenterol, 11, pp.112~ (2011)
- Lim SG, "The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use", Dig Liver Dis, 48, pp.385~390 (2016)
- 안병락, "Antibiotic Resistance in Helicobacter pylori Strains and its Effect on H. pylori Eradication Rates in a Single Center in Korea", Annals of Laboratory Medicine, 33(6), pp.415~419 (2013), 대한진단검사의학회
- Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Calvet X, "A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection", Aliment Pharmacol Ther, 14, pp.603~609 (2000)
- Ford A, "How can the current strategies for Helicobacter pylori eradication therapy be improved", Can J Gastroenterol, 17(Suppl B), pp.36B~40B (2003)
- Flores HB, "M1138 Duration of proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication : a meta-analysis", Gastroenterology, 138(5 Suppl 1), pp.S-340~ (2010)
- Malfertheiner P, "Helicobacter pylori eradication with a capsulecontaining bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy : a randomised, open-label, non-inferiority, phase 3trial", Lancet, 377, pp.905~913 (2011)
- Ford AC, "Adverse events with bismuth salts for Helicobacter pylori eradication : systematic review and meta-analysis", World J Gastroenterol, 14, pp.7361~7370 (2008)
- Fischbach L, "Meta-analysis : the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori", Aliment Pharmacol Ther, 26, pp.343~357 (2007)
- Graham DY, "Which therapy for Helicobacter pylori infection", Gastroenterology, 143, pp.10~12 (2012)
- Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
- 최원정, "서울 3차 의료기관에서 분리한 헬리코박터 파일로리항생제 내성률 변화", 대한내과학회지, 86(3), pp.308~313 (2014), 대한내과학회[DOI]
- Chung JW, "Ten-day sequential versus triple therapy for Helicobacter pylori eradication : a prospective, open-label, randomized trial", J Gastroenterol Hepatol, 27, pp.1675~1680 (2012)
- Park CS, "Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance", Am J Gastroenterol, 109, pp.1595~1602 (2014)
- Lee JY, "Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19genotype and antibiotic resistance", Dig Dis Sci, 59, pp.1235~1243 (2014)
- Kim SE, "Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes", World J Gastroenterol, 23, pp.1059~1066 (2017)
- Wolle K, "Antibiotic susceptibility of Helicobacter pylori in Germany : stable primary resistance from 1995 to 2000", J Med Microbiol, 51, pp.705~709 (2002)
- McMahon BJ, "The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections", Ann Intern Med, 139, pp.463~469 (2003)
- Zullo A, "Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy", Aliment Pharmacol Ther, 25, pp.1429~1434 (2007)
- Parsons HK, "Helicobacter pylori antimicrobial resistance in the United Kingdom : the effect of age, sex and socio-economic status", Aliment Pharmacol Ther, 15, pp.1473~1478 (2001)
- Prazeres Magalhaes P, "Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil", Antimicrob Agents Chemother, 46, pp.2021~2023 (2002)
- Megraud F, "Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption", Gut, 62, pp.34~42 (2013)
- Wong WM, "Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese", Aliment Pharmacol Ther, 21, pp.73~81 (2005)
- Chung SJ, "Eradication rates of helicobacter pylori infection with second-line treatment : non-ulcer dyspepsia compared to peptic ulcer disease", Hepatogastroenterology, 54, pp.1293~1296 (2007)
- Hojo M, "Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection", Scand J Gastroenterol, 36, pp.690~700 (2001)
- Graham DY, "Efficient identification and evaluation of effective Helicobacter pylori therapies", Clin Gastroenterol Hepatol, 7, pp.145~148 (2009)
- Lee BH, "Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection : effect of treatment duration and antibiotic resistance on the eradication rate in Korea", Helicobacter, 15, pp.38~45 (2010)
- Zullo A, "Bismuth-based quadruple therapy following H. pylori eradication failures : a multicenter study in clinical practice", J Gastrointestin Liver Dis, 26, pp.225~229 (2017)
- Perez Aldana L, "The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance", Helicobacter, 7, pp.306~309 (2002)
- Ortiz V, "Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low-resource Central America setting", Helicobacter, 24, pp.e12595~ (2019)